Government And Industry Backing Fueling The Surge In Nucleic Acid-Based Gene Therapy Demand: Core Growth Enabler in the Nucleic Acid Based Gene Therapy Market, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Nucleic Acid Based Gene Therapy Industry Market Size Be by 2025?
In recent years, the size of the market for nucleic acid-based gene therapy has seen significant growth. The market is projected to expand from $0.81 billion in 2024 to $0.88 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.4%. The historical growth rate can be traced back to factors such as an enhanced understanding of human genetics, increased interest in personalized medicine, a burgeoning pipeline of gene therapy products, increasing governmental support for gene therapy, as well as genetic disorders and cancer therapy.

What's the Long-Term Growth Forecast for the Nucleic Acid Based Gene Therapy Market Size Through 2029?
In the coming years, the nucleic acid based gene therapy market is projected to experience a swift expansion. The market value is anticipated to reach $1.33 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.7%. The predicted growth over this period can be credited to factors such as broadening indications, increased funding, enhanced patient advocacy and awareness, heightened investment in gene therapy research and development, a widening range of gene therapy applications, and treatment for rare diseases. Key trends for the said period comprise ex vivo gene editing, advancements in in vivo gene editing, combined therapies, specific delivery systems, gene editing aimed at rare diseases, and non-viral vectors.

View the full report here:
https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

What Are the Key Growth Drivers Fueling the Nucleic Acid Based Gene Therapy Market Expansion?
The anticipated increase in financial aid from the government and corporations is predicted to fuel demand for nucleic acid-based gene therapy. Nucleic acid medications are analogs of naturally occurring substances or proteins vital for genetic expression. Current therapies offer no solution for the treatment of diseases such as cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. Genetic profiling and identification of molecular targets are fundamental to these types of drugs. As these medications directly target the genetic foundation of diseases and offer a lasting cure, nucleic acid medications have more potential for the treatment of these illnesses. The anticipated rise in government and corporate financial aid for the gene therapy market is expected to boost the nucleic acid-based gene therapy market. For example, in August 2022, the National Institute of Health (NIH) pledged to invest $34 million per year for the next five years to advance HIV treatment research. This kind of support for gene therapies is poised to stimulate growth in the market for nucleic acid based gene therapy.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

What Are the Key Trends Driving Nucleic Acid Based Gene Therapy Market Growth?
In March 2023, a biotechnology firm based in the United States, Moderna, Inc., entered into a partnership with Generation Bio. The objective of this collaboration is for Moderna Inc. to create innovative nucleic acid treatments, particularly those that can target immune cells. This will speed up the non-viral genetics medicines pipelines for both companies and financially support all research and development related activities attached to this partnership, inclusive of early payments for research endeavors. Generation Bio is also a US-based biotechnology company specializing in nucleic acid-based gene therapy.

How Is the Nucleic Acid Based Gene Therapy Market Segmented?
The nucleic acid based gene therapy market covered in this report is segmented -

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies
2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases
3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:
1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)
2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies
3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)
4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs
5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes
6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers
7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2820&type=smp

Which Companies Are Leading the Charge in Nucleic Acid Based Gene Therapy Market Innovation?
Major companies operating in the nucleic acid based gene therapy market include Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

Which Regions Are Leading the Global Nucleic Acid Based Gene Therapy Market in Revenue?
North America was the largest region in the nucleic acid-based gene therapy market in 2023. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2820

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.